Wuxiao Liang

Associate

Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

pdf

Wuxiao Liang is an associate in O’Melveny’s Shanghai office. He has participated in projects covering mergers and acquisitions, capital markets, private equity/venture capital investment, joint ventures, outbound investments, foreign direct investments, and general corporate matters across various industries covering life sciences, technology, automotive, real estate, media and entertainment.

Wuxiao was the winner of 2015 O’Melveny & Myers Legal Scholarship. Prior to joining the firm, he interned with a Chinese domestic law firm and a Hong Kong listed company.

Languages

  • Mandarin Chinese
  • Cantonese
  • English

Honors & Awards

  • O’Melveny & Myers Shanghai Legal Scholarship
  • Ge Jun Talent Award, East China University of Political Science and Law

Admissions

  • New York

Education

  • Columbia Law School, LL.M.: Dean’s Honors, Best in Class Award
  • East China University of Political Science and Law, LL.B.: with highest honor

Professional Activities

Bar Exam

  • Passed Chinese Bar Exam

Editor

  • Yearbook on International Investment Law and Policy (Oxford University Press)
  • Columbia Journal of Asian Law
  • ABCI Captial Limited, CICC Hong Kong Securities Limited and other underwriters in the H-share IPO of Lushang Life Services Co., Ltd (2376.HK) on the Hong Kong Stock Exchange
  • Gushengtang Holdings Limited in its US$104 million IPO and listing on the Hong Kong Stock Exchange
  • Keymed Biosciences Inc. in its US$398 million IPO and listing on the Hong Kong Stock Exchange
  • a leading Shanghai-based clinical-stage drug development company in its US$117 million Series D and Series E financings and HK$867 million initial public offering
  • a leading China-based genomic company in its investment in and licensing technology from a U.K.-based genomic analytics company
  • a Shenzhen Stock Exchange listed company in its acquisition of a U.S.-based medical device manufacturer.
  • a Chinese listed medical company in its proposed investment in a NASDAQ-listed Israel clinical-stage biotherapy company
  • a leading Zhuhai-based monoclonal antibody drugs biotech in its US$150 million Series A financing
  • a leading Suzhou-based antibody therapeutics company in its Series C and C+ financing
  • an NYSE-listed U.S. radiation oncology equipment provider in its establishment of a joint venture enterprise with a Chinese state-owned company in China
  • a Shanghai-based state-owned investment management company in its PIPE investment in an NYSE-listed U.S. high-tech manufacture company
  • a leading Chinese information technology services provider listed on the Shenzhen Stock Exchange in its investment in a U.K.-based leading telematics company
  • a leading Hangzhou-based cloud computing and big data service provider in its Series B financing
  • a U.K.-based alternative energy technology company in its establishment of a joint venture enterprise with its Chinese partner in China
  • an NYSE-listed Chinese car rental service provider in its US$937.5 million management buyout transaction
  • an NYSE-listed online vehicle service provider in its US$165 million strategic investment in a leading Chinese online vehicle sales company
  • a famous Asian investment management group in its US$756 Million acquisition of three office towers in China
  • a Shenzhen Stock Exchange listed sport manufacture company in its proposed acquisition of a U.S.-based sport and entertainment company
  • a Hong Kong Stock Exchange listed holding company in its PIPE investment in an NYSE-listed leading theme park and entertainment company
  • a U.S.-based industrial group company in its investment in an NYSE-listed Chinese e-commerce company
  • General corporate matters of multinational companies’ subsidiaries and rep offices in China